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mass index (BMI) and the rate of progression of CKD has been less well studied.This
study aims to determine the relationship between BMI and progression of CKD
adjusted for major confounding factors.
METHODS: Retrospective, observational study in a cohort of adult patients with CKD
stage 4-5 not yet on dialysis. Patients with recent acute kidney injury or those with glo-
merular diseases or vasculitis under immunosuppressive therapy were excluded.The
slope of the regression line of eGFR (MDRD) over time (ml/min/1.73m2/year) was
used to assess the rate of renal failure progression.Patients were divided into 3 sub-
groups according to BMI:<25, 25-30, and>30 kg/m2.
RESULTS: The study group consisted of 915 patients (mean age 65614 years, 48%
women) with a median follow-up time of 23months. Mean eGFR slope was -
3.3564.44 ml/min/1.73m2/year.A BMI of 25 kg/m2 represented the cut-off point below
which the progression of CKD turn out to be faster. Themean decline of renal function
in this subgroup was significantly faster than the rest of the patients: -4.4164.77 vs. -
3.0664.31 ml/min/1.73m2/year (p<0.0001). These 196 patients with a BMI<25 kg/m2
were significantly younger, with less comorbidity, well controlled blood pressure with
less medication, lower markers of malnutrition and inflammation, and similar protei-
nuria, although the number of current smokers was significantly greater.Both BMI as a
continuous and as a dummy variable (BMI below 25 kg/m2) were significant and inde-
pendently associated with the rate of progression of CKD (ß¼ 0.103; p¼0.001, and ß
¼ -0.121; p<0.0001, respectively) in multivariate linear regression analysis adjusted
for age, sex, comorbidity, CKD etiology, blood pressure, proteinuria, and prescribed
medication.
CONCLUSIONS:While obesity is a risk factor for developing CKD, being thin is inde-
pendent and significantly associated with a faster progression of CKD at later stages.
This association cannot be explained by age, sex, comorbidity, malnutrition-inflamma-
tion, and it is independent of CKD etiology, blood pressure or proteinuria.
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INTRODUCTIONANDAIMS: Both of proteinuria and hyperphosphatemia are well
known risk factors of CKD progression. Recent experimental study reported that pro-
teinuria increases serum phosphate by decreasing biologic activity of fibroblast growth
factor 23 (FGF-23). We examined this relationship in a large chronic kidney disease
(CKD) cohort and evaluated combined effect of proteinuria and serum phosphate on
CKD progression.
METHODS: This prospective longitudinal study was conducted with 1909 patients
who were measured 24 hour urine protein (24h UP) and serum phosphate from the
KoreaN cohort study for Outcome in patients with CKD (KNOW-CKD). The activity
of FGF-23, measured by fractional excretion of phosphate (FEP)/FGF23 ratio, was
compared according to the degree of proteinuria. Primary outcome was CKD progres-
sion defined as50% decline of estimated glomerular filtration rate (eGFR), doubling
of serum creatinine, or start of dialysis.
RESULTS: Themean age was 53.96 12.1 years, and 60.8% of patients were male. The
mean eGFR was 50.66 30.4 mL/min/1.73m2. There was a significantly negative rela-
tionship between 24h UP and FEP/FGF-23 ratio after adjustment of multiple con-
founders (b, -0.06; P¼ 0.028). In addition, patients with more proteinuria had
significantly higher serum phosphate levels from CKD stage 2 to 5 than those with less
proteinuria. After matching variables associated with serum phosphate, patients with
more proteinuria had higher serum phosphate (P< 0.001) and FGF-23 (P¼ 0.045),
and lower FEP/FGF-23 ratio (P¼ 0.001) compared to those with less proteinuria. In
the propensity matched-cohort, 185 (21.7%) events of CKD progression were occurred
during the median follow-up of 33.2 months. Inmultivariable stratified Cox regression
model, low FEP/FGF-23 ratio was a significant risk factor of composite renal outcome
(hazard ratio, 0.90 per 1 log increase; 95% confidence interval, 0.82-0.99; P¼ 0.03).
Furthermore, there was a significant interaction between 24h UP and serum phosphate
on CKD progression (P< 0.001).
CONCLUSIONS: Proteinuria is associated with hyperphosphatemia and reduced bio-
logic activity of FGF-23. Furthermore, diminished activity of FGF23 is an independent
risk factor for renal progression in proteinuric CKD patients.
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INTRODUCTIONANDAIMS: Chronic kidney disease (CKD) is a common non-
communicable disease. Some but not all patients will progress to end stage renal disease
(ESRD), and this at different speeds. Accurate estimation of rate of progression is of
importance for individual prognostication, and in studies evaluating interventions to
slow down progression. Especially for this indication, high accuracy is essential. As
ESRD (the hard clinical endpoint) occurs only after a long period, there is a need for
surrogate endpoints. At present, there is no consensus on which surrogate endpoint to
use as metric. A variety of metrics is applied, and over different time frames, leading to
a lack of comparability between study results. We intended to investigate the agreement
among the most commonly used surrogate endpoints for progression of CKD to ESRD
to assess their impact on conclusions of studies.
METHODS: All serum creatinine values of a longitudinal cohort of 169 patients with
CKD attending the nephrology outpatient clinic of a university hospital were collected.
Patients were classified as progressors vs non progressor based on eleven different met-
rics within 3major categories: 1/ visual analysis of the data by a panel of 9 nephrologists
using three differently plotted graphs; 2/ interpretation based on commonly used sur-
rogate endpoints in clinical trials 3/ an analysis using composite endpoints. For 2 and 3,
a systematic search onmetrics used in RCTs was performed to select potential candi-
dates. For all different methods, inter rater reliability (IRR) was assessed based on the
Cohen’s kappa statistic.
RESULTS: All calculated Cohen’s kappa values stayed (far) beneath the required limit
for adequate agreement in healthcare research (for examples, see table). The panel of
nephrologists could not come to a coherent classification of a patient being a progressor
or not based on visual interpretation of eGFR graphs. Also, classification of patients
based on the surrogate endpoints currently used in research and on the assessed com-
posite endpoints to evaluate progression to ESRD was not consistent neither amongst
the different surrogate metrics nor with the nephrologists opinion. There was also a
lack of agreement between the samemetrics when used over 5 or 10 year timeframes.
CONCLUSIONS:Our results confirm a lack of agreed definition of progression of
CKD to ESKD using surrogate metrics. This confirmed lack of agreement is an impor-
tant issue, as conclusions of studies assessing interventions to slow down progression
apparently will differ based on the selected surrogate marker.
Examples of IRR
method 1 method 2 kappa 95%CI
Metric A 5 years Metric 10 10 years 0.59 0.30-0.89
Metric A 5 years Nephrologist panel 0.03 -0.13-0.14
Metric A 5 years Metric B 5 years 0.16 -0.01-0.30
Metric B at 5 years Nephrology panel 0.12 -0.07-0.31
FP319 NRF2 ACTIVATOR, RTADH404, ATTENUATES RENAL
TUBULAR INJURY VIA MITOCHONDRIAL PROTECTION IN
NEPHROTIC MODEL MICE
Yuji Sogawa1, Kidokoro, Yoshisuke Haruna, Minoru Satoh Hajime Nagasu,
Megumi Kondo, Yoshihisa Wada, Kengo, Tamaki Sasaki, Naoki Kashihara
1Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan
INTRODUCTIONANDAIMS:Nephrotic syndrome, including diabetic kidney dis-
eases (DKD), leads to renal failure due to severe proteinuria. Urinary protein is
resorbed in proximal tubular cells, and lipid peroxidation combined with albumin
induced reactive oxidative species (ROS) via mitochondrial dysfunction. These facts
suggested regulation of ROS is one of the therapeutic strategies for DKDwith proteinu-
ria. So, we focus on NF-E2-related factor 2 (Nrf2) which is a master regulator for the
cellular defense against oxidative stress. Recently study, tubulointerstitial damage by
ischemic-reperfusion injury was exacerbated in Nrf2 knockout mice (Nrf2KO). Nrf2
activator has a renoprotective effect by eliminating excessive ROS. However, the mech-
anisms of renoprotective effect are not fully understood, especially in DKD.We thus
investigated whether RTAdh404 attenuates proteinuria-induced renal tubular damage
via mitochondrial protection.
METHODS: To know the effect of RTAdh404 for proteinuria induced tubular injury,
Three-week-old male ICR-derived glomerulonephritis mice (ICGN), which develop
nephrotic syndrome, and ICRmice were used. Themice were divided into three
groups: ICR, ICGNþVehicle (Vehi), and ICGNþRTAdh404 (dh404). dh404 was dis-
solved in sesame oil and administered orally for three weeks (dh404;10mg/kg/day)).
Blood, urine and kidney tissue samples were harvested after 3 weeks of treatment.
Serum creatinine/urea nitrogen was evaluated as a renal function. Tubular damage was
evaluated by urinary N-GAL and KIM-1 staining. Fibrotic changes were evaluated by
masson staining and collagen IV staining. Mitochondrial function was assessed by
COX staining and transmission electron microscope (TEM). Next, in vitro study,
human proximal tubular epithelial cells (hPTECs) were used to determine the mecha-
nism of renal protective effect by dh404. hPTECwere stimulated with bovine serum
albumin(BSA) binding to free fatty acid (FFA) and treated with or without dh404 for
six hours.
RESULTS: In ICGNþVehi groups, renal function, based on the serum creatinine and
urea nitrogen, was significantly exacerbated. dH404 was able to attenuate renal dys-
function in ICGNmice. Then Tubulointerstitial injury and fibrotic change were signifi-
cantly worsened. Mitochondrial respiratory enzyme and the mitochondrial formation
were injured. These damages were improved in ICGNþdh404 groups. These data sug-
gest that RTAdh404 has a renoprotective effect via mitochondrial protection. In vitro
Abstracts Nephrology Dialysis Transplantation
i138 | Abstracts
Downloaded from https://academic.oup.com/ndt/article-abstract/33/suppl_1/i138/4997422
by Ghent University user
on 20 July 2018
